Immediate Autoimmune Antibody Testing and Urgent Neurology Referral
This patient requires immediate serum testing for AQP4-IgG and MOG-IgG antibodies to differentiate neuromyelitis optica spectrum disorder (NMOSD) from MOG-associated disease (MOGAD), as the extensive longitudinal cord involvement with optic nerve findings strongly suggests NMOSD rather than multiple sclerosis, and early immunotherapy initiation is critical to prevent irreversible disability. 1
Primary Differential Diagnosis Framework
The MRI pattern of extensive cervical and thoracic cord demyelination without enhancement creates a specific diagnostic hierarchy:
Most Likely: NMOSD (Neuromyelitis Optica Spectrum Disorder)
- Extensive longitudinal cord involvement spanning entire cervical and thoracic regions is characteristic of NMOSD
- Optic nerve involvement on brain MRI combined with cord pathology is pathognomonic for NMOSD
- Central cord location of lesions (as opposed to peripheral white matter) favors NMOSD over MS 1
- The absence of enhancement does not exclude NMOSD—enhancement patterns vary by disease phase
Alternative: MOGAD (MOG-Antibody Associated Disease)
- Can present with similar extensive cord involvement
- Central grey matter involvement (H-sign) more typical of MOGAD
- Enhancement less frequent in acute phase compared to NMOSD 1
Less Likely: Multiple Sclerosis
- The pattern is atypical for MS because MS typically shows short-segment lesions (<2 vertebral segments)
- MS cord lesions are usually peripheral, wedge-shaped, and involve peripheral white matter 1
- The extensive diffuse involvement makes MS unlikely despite being the most common demyelinating disease
Critical Follow-Up Actions (In Order of Priority)
1. Urgent Serological Testing
- AQP4-IgG (aquaporin-4 antibody): Positive in 70-80% of NMOSD cases
- MOG-IgG (myelin oligodendrocyte glycoprotein antibody): Defines MOGAD
- These tests must be sent immediately as they determine treatment strategy
2. Comprehensive Ophthalmologic Evaluation
- Formal visual field testing
- Optical coherence tomography (OCT) to assess optic nerve damage
- Document baseline visual function before potential future attacks
3. Complete Spinal Imaging Review
- The current MRI shows no syrinx despite Chiari I malformation 2
- This is reassuring but requires documentation as syrinx can develop
4. CSF Analysis
- Oligoclonal bands (typically negative or weakly positive in NMOSD, unlike MS)
- Cell count and protein (often elevated in NMOSD acute attacks)
- Rule out infectious/inflammatory mimics
Addressing the Mechanical Components
The C5-6 Severe Left Foraminal Stenosis
This creates a dual pathology scenario requiring careful attribution:
Radicular symptoms from stenosis would include:
- Dermatomal sensory loss (C6 distribution: thumb and index finger)
- Myotomal weakness (biceps, wrist extensors)
- Reduced biceps reflex
- Sharp, shooting pain down the arm in specific distribution
Myelopathic symptoms from demyelination would include:
- Non-dermatomal sensory changes
- Upper motor neuron signs (hyperreflexia, spasticity)
- Bilateral symptoms or symptoms below the lesion level
- Diffuse, poorly localized pain and weakness
The severe left C5-6 foraminal stenosis likely contributes to focal left arm symptoms, but the extensive cord demyelination is the dominant pathology. 3 The disc protrusion may require eventual surgical consideration, but only after the demyelinating disease is controlled and stabilized.
The Chiari I Malformation
- Currently asymptomatic (no syrinx, no hydrocephalus) 2
- Does not require immediate intervention
- Can be monitored with serial imaging
- Common pitfall: Attributing all symptoms to incidental Chiari I when demyelinating disease is the actual cause 4
Treatment Implications Based on Diagnosis
If AQP4-IgG Positive (NMOSD):
- Immediate immunosuppression with rituximab, satralizumab, or inebilizumab
- High-dose corticosteroids for acute attack if symptomatic
- Avoid MS therapies (interferon-beta, natalizumab) which can worsen NMOSD
- Aggressive attack prevention is critical—NMOSD attacks cause cumulative irreversible damage
If MOG-IgG Positive (MOGAD):
- Corticosteroids for acute attacks
- Maintenance immunotherapy (IVIG, rituximab, or mycophenolate)
- Generally better prognosis than AQP4+ NMOSD
- Some patients have monophasic course
If Both Antibodies Negative (Seronegative NMOSD or Other):
- Clinical diagnosis still possible with typical MRI pattern
- May require repeat antibody testing
- Consider other rare causes: sarcoidosis, paraneoplastic syndromes
Critical Pitfalls to Avoid
- Delaying antibody testing while pursuing conservative management—every day without diagnosis risks another attack
- Treating as MS empirically—MS disease-modifying therapies can catastrophically worsen NMOSD
- Attributing all symptoms to the Chiari I malformation—the demyelinating disease is the primary pathology 5, 4
- Rushing to cervical spine surgery—the foraminal stenosis should be addressed only after demyelinating disease is controlled and if symptoms clearly localize 4
- Missing the urgency—NMOSD attacks can cause permanent paralysis and blindness; prevention is paramount
Monitoring Strategy
- Immediate: Neurology consultation within 48-72 hours
- Short-term: Repeat MRI in 3-6 months to assess for new lesions or enhancement
- Long-term: Annual MRI surveillance once diagnosis established and treatment initiated
- Functional: Serial neurological examinations documenting motor, sensory, and sphincter function
The shoulder pain and arm weakness represent a combination of radiculopathy from mechanical compression and myelopathy from demyelination, but the extensive demyelinating process poses the greater threat to long-term neurological function and must be the immediate focus of diagnostic and therapeutic efforts.